← All trials
NCT05184088
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Jun 30, 2024
- Completion date
- Sep 30, 2024
- First posted
- Jan 11, 2022
- Last posted
- Dec 15, 2022
- Enrollment
- 200
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- PiramalLead sponsor
- pharmtrace klinische Entwicklung GmbHCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.